MockV Solutions, Inc. (MockV or the Company), a biotechnology company developing non-infectious viral clearance prediction products that address the unmet needs of process development scientists as they establish biopharmaceutical manufacturing platforms, announced today the receipt of a Phase I grant from the National Center for Advancing Translations Sciences under auspices of the Small Business Innovation Research (SBIR) program of the National Institutes of Health. The $250,000 grant under the Award Number R43TR002231 is focused on demonstrating the utility of a non-infectious Minute Virus of Mice-Virus Like Particle for predicting viral clearance during biopharmaceutical process development.